{"id":390534,"date":"2018-12-05T00:00:00","date_gmt":"2018-12-05T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0005-2018-biopharma-multiple-myeloma-disease-landscape-and-forecast-g7-2018\/"},"modified":"2026-04-29T11:39:55","modified_gmt":"2026-04-29T11:39:55","slug":"dlsfon0005-2018-biopharma-multiple-myeloma-disease-landscape-and-forecast-g7-2018","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0005-2018-biopharma-multiple-myeloma-disease-landscape-and-forecast-g7-2018\/","title":{"rendered":"Multiple Myeloma | Disease Landscape and Forecast | G7 | 2018"},"content":{"rendered":"<p><strong>Market Outlook<\/strong><\/p>\n<p>Celgene\u2019s Revlimid and Janssen\/Takeda Pharmaceutical\u2019s Velcade are the cornerstones of therapy for multiple myeloma. Successive label expansions have driven significant commercial reward for some well-entrenched current therapies. Emerging agents such as AbbVie\/Roche\/Genentech\u2019s Venclexta\/Venclyxto, Karyopharm Therapeutics\u2019 selinexor, Sanofi\/ImmunoGen\u2019s isatuximab, and Bluebird Bio\/Celgene\u2019s\u00a0bb2121 are pursuing initial approvals for the treatment of multiple myeloma, highlighting that untapped clinical and commercial potential exists in multiple myeloma for therapies with improved efficacy, novel mechanisms of action, and positioned in patient segments that are currently underserved.<\/p>\n<p><strong>Questions Answered<\/strong><\/p>\n<ul>\n<li>Revlimid and Velcade are widely used for the current treatment of multiple myeloma, but how will the use of these agents change over the forecast period? What impact will generic entries of these pivotal agents have on the multiple myeloma market?<\/li>\n<li>How has the approval of Janssen\u2019s Darzalex and Bristol-Myers Squibb\/AbbVie\u2019s Empliciti impacted the multiple myeloma market? How important will these agents become over the forecast period?<\/li>\n<li>What are thought-leaders\u2019 opinions on agents in Phase III development, such as Merck &#038; Co.\u2019s Keytruda, Bristol-Myers Squibb\/Ono Pharmaceutical\u2019s Opdivo, Sanofi\/ImmunoGen\u2019s isatuximab, Bluebird Bio\/Celgene\u2019s bb2121, and\u00a0GlaxoSmithKline\u2019s GSK2857916? What impact will these agents have on the multiple myeloma market?<\/li>\n<li>What are the drivers and constraints in the multiple myeloma market, and how will the market evolve over the forecast period?<\/li>\n<\/ul>\n<p><strong>Product Description<\/strong><\/p>\n<p>Disease Landscape &#038; Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.<\/p>\n","protected":false},"template":"","class_list":["post-390534","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-multiple-myeloma","biopharma-date-920"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390534","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390534\/revisions"}],"predecessor-version":[{"id":576681,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390534\/revisions\/576681"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390534"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}